Loading patent…
AssigneeMUSC Foundation for Research Development
InventorsHongkuan Fan, Andrew Goodwin, Perry V. Halushka, James A. Cook, Yue Zhou
Estimating the term…
The presently disclosed subject matter relates to isolated compositions and methods for treating and/or preventing sepsis and inflammatory conditions, such as Acute Respiratory Distress Syndrome (ARDS). In some embodiments, the presently disclosed subject matter relates to endothelial progenitor cell-derived exosomes to treat and/or prevent sepsis and inflammatory conditions, such as Acute Respiratory Distress Syndrome (ARDS). The endothelial progenitor cell-derived exosomes can be modified to overexpress one or more miRNAs
A method for treating and/or preventing sepsis in a subject, the method comprising administering to a subject a composition comprising, consisting essentially of, or consisting of a therapeutically effective amount of endothelial progenitor cell-derived exosomes.
A method for treating and/or preventing an inflammatory condition in a subject, the method comprising administering to a subject a composition comprising, consisting essentially of, or consisting of a therapeutically effective amount of endothelial progenitor cell-derived exosomes.
4-5. (canceled)
A pharmaceutical composition comprising, consisting essentially of, or consisting of a therapeutically effective amount of endothelial progenitor cell-derived exosomes for treating and/or preventing sepsis in a subject.
7-8. (canceled)
A pharmaceutical composition comprising, consisting essentially of, or consisting of a therapeutically effective amount of endothelial progenitor cell-derived exosomes for treating and/or preventing an inflammatory condition in a subject.
An endothelial progenitor cell-derived exosome, wherein the endothelial progenitor cell-derived exosome comprises one or more modifications that enhance expression of an miR-126 microRNA in the endothelial progenitor cell-derived exosome.
(canceled)
Dependencies are inferred from the claim text.